John M. Climaco - 01 Feb 2024 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Role: Chief Executive Officer, Director
Signature: /s/ Christopher Downs, Attorney-in-Fact
Issuer symbol: CNSP
Transactions as of: 01 Feb 2024
Net transactions value: +$50,000
Form type: 4
Filing time: 06 Feb 2024, 10:27:23 UTC
Previous filing: 16 Aug 2023
Next filing: 10 Apr 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CNSP	Common stock	Purchase	$50,000	+166,666	+340%	$0.3000	215,676	01 Feb 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CNSP	Series A Warrant to purchase common stock	Award		+166,666	+277%		226,867	01 Feb 2024	Common Stock	166,666	$0.3000	Direct	F1
transaction	CNSP	Series B Warrant to purchase common stock	Award		+166,666	+73%		393,533	01 Feb 2024	Common Stock	166,666	$0.3000	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.